Editas Medicine (Editas Medicine) Total Liabilities : $150.06 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Total Liabilities?

Editas Medicine's Total Liabilities for the quarter that ended in Dec. 2023 was $150.06 Mil.

Editas Medicine's quarterly Total Liabilities increased from Jun. 2023 ($142.04 Mil) to Sep. 2023 ($144.19 Mil) and increased from Sep. 2023 ($144.19 Mil) to Dec. 2023 ($150.06 Mil).

Editas Medicine's annual Total Liabilities increased from Dec. 2021 ($123.84 Mil) to Dec. 2022 ($153.64 Mil) but then declined from Dec. 2022 ($153.64 Mil) to Dec. 2023 ($150.06 Mil).

Editas Medicine Total Liabilities Historical Data

The historical data trend for Editas Medicine's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Total Liabilities Chart

Editas Medicine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

246.45

179.02

123.84

153.64

150.06

Editas Medicine Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															153.64	146.63	142.04	144.19	150.06

Editas Medicine Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Editas Medicine's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	63.217	+	(24.372	+	1.8
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	60.667	+	0)
	=	150.06

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	499.153	-	349.097
	=	150.06

Editas Medicine's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	63.217	+	(24.372	+	1.8
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	60.667	+	0)
	=	150.06

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	499.153	-	349.097
	=	150.06

Editas Medicine Total Liabilities Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine (Editas Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

8EM:Germany 8EM:Germany

Address

11 Hurley Street, Cambridge, MA, USA, 02141

Website

https://www.editasmedicine.com

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Executives

Bruce Eaton	officer: EVP, Chief Business Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Linda Burkly	officer: EVP, CHIEF SCIENTIFIC OFFICER	1 MAIN STREET, CAMBRIDGE MA 02142
Baisong Mei	officer: SVP, CHIEF MEDICAL OFFICER	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill	director, officer: CEO	215 FIRST STREET, CAMBRIDGE MA 02142
Erick Lucera	officer: EVP, CHIEF FINANCIAL OFFICER	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Michelle Robertson	officer: Chief Financial Officer	C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman	officer: EVP, Chief Scientific Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels	officer: EVP/Chief Medical Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton	director	C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen	director	940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142